Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Stereotactic Radiotherapy for the Treatment of Patients With Oligo-progressive Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor: Data From the Real World

VITTORIO GEBBIA, ANDREA GIRLANDO, ALFIO DI GRAZIA, IVAN FAZIO, NICOLÒ BORSELLINO, DARIO PIAZZA, VINCENZO SERRETTA, STEFANO PERGOLIZZI, ANTONIO PONTORIERO, ALBERTO FIRENZE and MARIA ROSARIA VALERIO
Anticancer Research December 2020, 40 (12) 7037-7043; DOI: https://doi.org/10.21873/anticanres.14730
VITTORIO GEBBIA
1Oncology Section, Department Promise, University of Palermo, Palermo, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: vittorio.gebbia{at}gmail.com
ANDREA GIRLANDO
4Radiation Therapy Unit, Istituto Clinico Humanitas, Catania, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ALFIO DI GRAZIA
5Radiation Therapy Unit, Istituto Oncologico del Mediterraneo, Catania, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
IVAN FAZIO
6Radiation Therapy Unit, Casa di Cura Macchiarella, Palermo, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NICOLÒ BORSELLINO
7Medical Oncology Unit, Ospedale Buccheri La Ferla, Palermo, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DARIO PIAZZA
3GSTU Foundation, Group for the Study of Urologic Tumors, Palermo, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
VINCENZO SERRETTA
3GSTU Foundation, Group for the Study of Urologic Tumors, Palermo, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
STEFANO PERGOLIZZI
9Dipartimento Biomorf, Università di Messina, Messina, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANTONIO PONTORIERO
10UO Radioterapia, Azienda Ospedaliera Policlinico G. Martino, Messina, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ALBERTO FIRENZE
11Risk Management Unit, Policlinico, University of Palermo, Palermo, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARIA ROSARIA VALERIO
12Medical Oncology Unit, Policlinico, University of Palermo, Palermo, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 40 no. 12 7037-7043
DOI 
https://doi.org/10.21873/anticanres.14730
PMID 
33288600

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received July 22, 2020
  • Revision received October 14, 2020
  • Accepted October 15, 2020
  • Published online December 7, 2020.

Copyright & Usage 
Copyright © 2020 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Author Information

  1. VITTORIO GEBBIA⇑1,
  2. ANDREA GIRLANDO4,
  3. ALFIO DI GRAZIA5,
  4. IVAN FAZIO6,
  5. NICOLÒ BORSELLINO7,
  6. DARIO PIAZZA3,
  7. VINCENZO SERRETTA3,
  8. STEFANO PERGOLIZZI9,
  9. ANTONIO PONTORIERO10,
  10. ALBERTO FIRENZE11 and
  11. MARIA ROSARIA VALERIO12
  1. 1Oncology Section, Department Promise, University of Palermo, Palermo, Italy;
  2. 2Medical Oncology Unit, La Maddalena Clinic for Cancer, Palermo, Italy;
  3. 3GSTU Foundation, Group for the Study of Urologic Tumors, Palermo, Italy;
  4. 4Radiation Therapy Unit, Istituto Clinico Humanitas, Catania, Italy;
  5. 5Radiation Therapy Unit, Istituto Oncologico del Mediterraneo, Catania, Italy;
  6. 6Radiation Therapy Unit, Casa di Cura Macchiarella, Palermo, Italy;
  7. 7Medical Oncology Unit, Ospedale Buccheri La Ferla, Palermo, Italy;
  8. 8Urology Unit, Policlinico, University of Palermo, Palermo, Italy;
  9. 9Dipartimento Biomorf, Università di Messina, Messina, Italy;
  10. 10UO Radioterapia, Azienda Ospedaliera Policlinico G. Martino, Messina, Italy;
  11. 11Risk Management Unit, Policlinico, University of Palermo, Palermo, Italy;
  12. 12Medical Oncology Unit, Policlinico, University of Palermo, Palermo, Italy
  1. Correspondence to: Vittorio Gebbia, MD, Ph.D., Medical Oncology Unit, La Maddalena Clinic for Cancer, via San Lorenzo Colli n. 312d, 90100, Palermo, Italy. Tel: +39 0916806710, e-mail: vittorio.gebbia{at}gmail.com
View Full Text

Statistics from Altmetric.com

Cited By...

  • 13 Citations
  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 40, Issue 12
December 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Stereotactic Radiotherapy for the Treatment of Patients With Oligo-progressive Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor: Data From the Real World
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
3 + 7 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Stereotactic Radiotherapy for the Treatment of Patients With Oligo-progressive Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor: Data From the Real World
VITTORIO GEBBIA, ANDREA GIRLANDO, ALFIO DI GRAZIA, IVAN FAZIO, NICOLÒ BORSELLINO, DARIO PIAZZA, VINCENZO SERRETTA, STEFANO PERGOLIZZI, ANTONIO PONTORIERO, ALBERTO FIRENZE, MARIA ROSARIA VALERIO
Anticancer Research Dec 2020, 40 (12) 7037-7043; DOI: 10.21873/anticanres.14730

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Stereotactic Radiotherapy for the Treatment of Patients With Oligo-progressive Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor: Data From the Real World
VITTORIO GEBBIA, ANDREA GIRLANDO, ALFIO DI GRAZIA, IVAN FAZIO, NICOLÒ BORSELLINO, DARIO PIAZZA, VINCENZO SERRETTA, STEFANO PERGOLIZZI, ANTONIO PONTORIERO, ALBERTO FIRENZE, MARIA ROSARIA VALERIO
Anticancer Research Dec 2020, 40 (12) 7037-7043; DOI: 10.21873/anticanres.14730
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Conclusion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • A Reminder App for Optimizing Bladder Filling During Radiotherapy for Prostate Cancer: A Pre-study in Healthy Volunteers
  • Timing and Risk Factors for Hyperglycemia Associated With Anamorelin Administration
  • Identification of Risk Factors for the Local Recurrence of Hepatocellular Carcinoma Post-radiofrequency Ablation
Show more Clinical Studies

Keywords

  • Renal cell carcinoma
  • metastasis
  • Pazopanib
  • stereotactic radiotherapy
  • tyrosine kinase inhibitors
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire